Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial

Author： Nicholls Stephen   Cavender Matthew   Kastelein John   Schwartz Gregory   Waters David   Rosenson Robert   Bash Dianna   Hislop Colin  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.26, Iss.1, 2012-02, pp. : 71-75

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Inflammation and Allergy in Acute Coronary Syndromes

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 7, Iss. 3, 2008-09 ,pp. : 136-144

Bentham Science Publishers

Access to resources Recommend Favorite

Fondaparinux in acute coronary syndromes

By Chaturvedi Vivek   Karthikeyan Ganesan  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 12, 2009-12 ,pp. : 1615-1623

Informa Healthcare

Access to resources Recommend Favorite

Acute Coronary Syndromes in the Elderly

By Kyriakides Zenon S.   Kourouklis Spyros   Kontaras Konstantinos  

Drugs & Aging, Vol. 24, Iss. 11, 2007-01 ,pp. : 901-912

Adis International

Access to resources Recommend Favorite

Acute coronary syndromes

By McClelland Anthony J J   Owens Colum G   Walsh Simon   Adgey A A Jennifer  

Clinical Medicine, Vol. 4, Iss. 1, 2004-01 ,pp. : 27-31

Royal College Of Physicians

Access to resources Recommend Favorite

Acute coronary syndromes

By Kapur Akhil  

Clinical Medicine, Vol. 5, Iss. 4, 2005-07 ,pp. : 406-408

Royal College Of Physicians

Access to resources Recommend Favorite